8 versus 12 weeks of percutaneous tibial nerve stimulation and response predictors for overactive bladder

  • Carrie E. JungEmail author
  • Shawn A. Menefee
  • Gouri B. Diwadkar
Original Article


Introduction and hypothesis

The primary objective is to compare weekly success rates after 8 vs 12 weekly percutaneous tibial nerve stimulation (PTNS) sessions for treatment of overactive bladder (OAB) in women and the secondary objective is to identify treatment response predictors.


A retrospective study of 470 women was performed with the primary definition of success a Patient Global Impression-Improvement (PGI-I) score of 1 (“very much better”) or 2 (“much better”) and a ≥ 10-point improvement in both subscales of the Overactive Bladder Questionnaire-Short Form (OABq-SF). Additional analyses were performed to include a success definition of a PGI-I score of 3 (“a little better”). Categorical variables were compared using the Chi-squared test. Multivariate logistic regression was performed to identify factors associated with response.


One hundred and thirty-six out of 470 (29%) discontinued treatment before 12 weeks. One hundred out of 334 (29.9%) were successes at 8 weeks vs 138 out of 334 (41.3%) at 12 weeks (p = 0.002). Including a PGI-I score of 3 as an indicator of success, 181 out of 334 (54.2%) at 8 weeks and 202 out of 334 (60.5%) at 12 weeks were successes (p = 0.10). Factors associated with treatment response were neurological disorder (OR 4.32 [1.10–16.04]), prolapse surgery history (OR 3.89 [1.12–14.49]), and vaginal estrogen use (OR 1.76 [1.01–3.08]). Recurrent UTI was associated with failure (OR 0.42 [0.21–0.86]).


The PTNS treatment success rate for OAB in women is greater at 12 weeks than at 8 weeks based on two validated questionnaires, the PGI-I and the OABq-SF. However, the success rates were equivalent if women who are “a little better” are also considered successes; with this definition, clinicians may consider shortening treatment duration to 8 weeks. Four clinical factors were significantly associated with response and may help to guide patient selection.


Overactive bladder Neuromodulation Tibial nerve Therapeutics 



Su-Jau Yang, PhD, biostatistician (Kaiser Permanente Southern California Department of Research & Evaluation).


This research was supported by a grant from the Regional Research Committee of Kaiser Permanente Southern California (RRC grant number: KP-RRC-20170503).

Compliance with ethical standards

Conflicts of interest

The authors declare that they have no conflicts of interest.

Supplementary material

192_2019_4191_MOESM1_ESM.docx (13 kb)
ESM 1 (DOCX 12 kb)


  1. 1.
    Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327–36.CrossRefGoogle Scholar
  2. 2.
    Coyne KS, Sexton CC, Vats V, Thompson C, Kopp ZS, Milsom I. National community prevalence of overactive bladder in the United States stratified by sex and age. Urology. 2011;77(5):1081–7.CrossRefGoogle Scholar
  3. 3.
    Ganz ML, Smalarz AM, Krupski TL, et al. Economic costs of overactive bladder in the United States. Urology. 2010;75(3):526–532.e1–18.CrossRefGoogle Scholar
  4. 4.
    Peters KM, Carrico DJ, Perez-Marrero RA, et al. Randomized trial of percutaneous tibial nerve stimulation versus sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol. 2010;183(4):1438–43.CrossRefGoogle Scholar
  5. 5.
    Peters KM, Carrico DJ, MacDiarmid SA, et al. Sustained therapeutic effects of percutaneous tibial nerve stimulation: 24-month results of the STEP study. Neurourol Urodyn. 2013;32(1):24–9.CrossRefGoogle Scholar
  6. 6.
    Finazzi-Agrò E, Petta F, Sciobica F, Pasqualetti P, Musco S, Bove P. Percutaneous tibial nerve stimulation effects on detrusor overactivity incontinence are not due to a placebo effect: a randomized, double-blind, placebo controlled trial. J Urol. 2010;184(5):2001–6.CrossRefGoogle Scholar
  7. 7.
    Yoong W, Ridout AE, Damodaram M, Dadswell R. Neuromodulative treatment with percutaneous tibial nerve stimulation for intractable detrusor instability: outcomes following a shortened 6-week protocol. BJU Int. 2010;106(11):1673–6.CrossRefGoogle Scholar
  8. 8.
    Lippman QK, Lingenfelter D, Menefee SA, et al. Duration of percutaneous tibial nerve stimulation (PTNS) for overactive bladder: is 12 weeks superior to 8 weeks of treatment? The Annual Meeting of the American Urogynecologic Society; 11–15 October 2016.Google Scholar
  9. 9.
    Yalcin I, Bump RC. Validation of two global impression questionnaires for incontinence. Am J Obstet Gynecol. 2003;189(1):98–101.CrossRefGoogle Scholar
  10. 10.
    Matza LS, Thompson CL, Krasnow J, Brewster-Jordan J, Zyczynski T, Coyne KS. Test-retest reliability of four questionnaires for patients with overactive bladder: the overactive bladder questionnaire (OAB-q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ). Neurourol Urodyn. 2005;24(3):215–25.CrossRefGoogle Scholar
  11. 11.
    Coyne KS, Matza LS, Thompson C, Jumadilova Z, Bavendam T. The responsiveness of the OAB-q among OAB patient subgroups. Neurourol Urodyn. 2007;26(2):196–203.CrossRefGoogle Scholar
  12. 12.
    Fok CS, McKinley K, Mueller ER, et al. Day of surgery urine cultures identify urogynecologic patients at increased risk for postoperative urinary tract infection. J Urol. 2013;189(5):1721–4.CrossRefGoogle Scholar
  13. 13.
    Coyne KS, Matza LS, Thompson CL, Kopp ZS, Khullar V. Determining the importance of change in the overactive bladder questionnaire. J Urol. 2006;176(2):627–632; discussion 632.CrossRefGoogle Scholar
  14. 14.
    Dyer KY, McKinley K, Mueller ER, et al. Minimum important difference for validated instruments in women with urge incontinence. Neurourol Urodyn. 2011;30(7):1319–24.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Visco AG, Brubaker L, Richter HE, et al. Anticholinergic therapy vs. onabotulinumtoxinA for urgency urinary incontinence. N Engl J Med. 2012;367(19):1803–13.CrossRefGoogle Scholar
  16. 16.
    Amundsen CL, Richter HE, Menefee SA, et al. OnabotulinumtoxinA vs sacral neuromodulation on refractory urgency urinary incontinence in women. JAMA. 2016;316(13):1366.CrossRefGoogle Scholar
  17. 17.
    Peters KM, Macdiarmid SA, Wooldridge LS, et al. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. J Urol. 2009;182(3):1055–61.CrossRefGoogle Scholar
  18. 18.
    Furtado-Albanezi D, Jürgensen SP, Avila MA, Correia GN, Driusso P. Effects of two nonpharmacological treatments on the sleep quality of women with nocturia: a randomized controlled clinical trial. Int Urogynecol J. 2019;30(2):279–86.CrossRefGoogle Scholar
  19. 19.
    Kershaw V, Khunda A, McCormick C, Ballard P. The effect of percutaneous tibial nerve stimulation (PTNS) on sexual function: a systematic review and meta-analysis. Int Urogynecol J., 2019;30(10):1619–27.CrossRefGoogle Scholar
  20. 20.
    Amundsen CL, Romero AA, Jamison MG, Webster GD. Sacral neuromodulation for intractable urge incontinence: are there factors associated with cure? Urology. 2005;66(4):746–50.CrossRefGoogle Scholar
  21. 21.
    Ruud Bosch JL, Groen J. Treatment of refractory urge urinary incontinence with sacral spinal nerve stimulation in multiple sclerosis patients. Lancet. 1996;348(9029):717–9.CrossRefGoogle Scholar
  22. 22.
    Chartier-Kastler EJ, Ruud Bosch JL, Perrigot M, Chancellor MB, Richard F, Denys P. Long-term results of sacral nerve stimulation (S3) for the treatment of neurogenic refractory urge incontinence related to detrusor hyperreflexia. J Urol. 2000;164(5):1476–80.CrossRefGoogle Scholar
  23. 23.
    Rostaminia G, Chang C, Pincus JB, Sand PK, Goldberg RP. Predictors of successful percutaneous tibial nerve stimulation (PTNS) in the treatment of overactive bladder syndrome. Int Urogynecol J. 2018;30(10):1735–45.CrossRefGoogle Scholar
  24. 24.
    Rachaneni S, Latthe P. Effectiveness of BTX-A and neuromodulation in treating OAB with or without detrusor overactivity: a systematic review. Int Urogynecol J. 2017;28(6):805–16.CrossRefGoogle Scholar
  25. 25.
    Iyer S, Laus K, Rugino A, et al. Subjective and objective responses to PTNS and predictors for success: a retrospective cohort study of percutaneous tibial nerve stimulation for overactive bladder. Int Urogynecol J. 2018;30(8):1253–9.CrossRefGoogle Scholar

Copyright information

© The International Urogynecological Association 2020

Authors and Affiliations

  1. 1.Department of Obstetrics and Gynecology; Division of UrogynecologyKaiser Permanente, Southern CaliforniaSan DiegoUSA
  2. 2.Division of Female Pelvic Medicine and Reconstructive SurgerySan DiegoUSA

Personalised recommendations